In November, the amount of holdings in the pharmaceutical and biological industry exceeded 100 million yuan

Looking back at the increase in shares held by the directors, supervisors and senior executives of listed companies on the Shanghai and Shenzhen stock exchanges in November and their affiliates, the cumulative increase in holdings during the month was approximately 421 million yuan, involving 91 companies
.
Among them, the amount of increase in holdings in the pharmaceutical and biological industries topped the list, with a cumulative total of over 100 million yuan, followed by computers and mechanical equipment, both exceeding 50 million yuan
.
In November, the amount of increase in holdings in the pharmaceutical and biological industry was dazzling, with a total amount of approximately 101 million yuan.
The high amount of increase in holdings mainly came from Garden Biology and Jinshiya
.
According to the data, Huayuan Biotechnology was increased by senior executives from November 3 to November 16, with a cumulative increase of 2,454,200 shares, and the total amount of increased holdings was 32,990,100 yuan
.
According to the announcement issued by Garden Bio-Bio on the evening of November 11, on November 11, 2021, the company received the "Notification Letter on the Implementation Progress of the Company's Share Increase Plan" issued by Chairman Mr.
Shao Xujun
.
Mr.
Shao Xujun accumulatively increased his holdings of the company’s shares by about 1.
5 million shares through centralized bidding on November 9, November 10, and November 11, 2021 with his own funds, and the accumulated holding amount was 20 million yuan
.
It is reported that before the increase in holdings, Shao Xujun did not hold the company's shares
.
After the increase in holdings, Mr.
Shao Xujun held a total of 1.
5365 million shares of the company, accounting for 0.
2729% of the company's total share capital
.
Garden Bio's main business is the research and development, production and sales of vitamin D3 upstream and downstream products.
It is a giant vitamin D3 manufacturer
.
Data show that VD3 is widely used in feed additives, food additives, nutritional health products and biomedicine products
.
In the first three quarters of this year, the company's performance turned losses into profits, realized operating income of 313 million yuan, net profit of 123 million yuan, net profit of 113 million yuan after deducting non-recurring gains and losses, and net operating cash flow of 262 million yuan
.
The company explained that the reason for the substantial increase in performance is that since 2021, the four products of the Garden Pharmaceutical Industry have been selected for the centralized procurement of national drugs
.
Chen Shaohong, an executive of Jinshi Asia Pharmaceuticals, accumulated a total of 27.
13 million yuan in holdings in November
.
The company is mainly engaged in the research and development and manufacturing of medical health and special equipment technology.

.
On the evening of October 26, the company issued a third-quarter results announcement, stating that the third quarter achieved operating income of approximately 196 million yuan, a year-on-year increase of 33.
59%
.
The net profit attributable to shareholders of the listed company was approximately RMB 6.
81 million
.
Realize basic earnings per share of 0.
02 yuan
.
In addition, on November 10, 2021, Huang Lequn, chairman of Qianyuan Pharmaceutical, used his own funds to increase his holding of the company’s shares by a centralized bidding method through the Shenzhen Stock Exchange’s securities trading system by about 200,000 shares, accounting for 0.
0883% of the company’s total share capital.
Increase holdings of 8,661,100 yuan
.
The announcement shows that before the increase, Huang Lequn held a total of 4.
9636 million shares of the company.
After the increase, he holds 51.
65 million shares, accounting for 2.
2657% of the company's total equity
.
Qianyuan Medicine is mainly engaged in the research and development, production, sales of medicines and health foods, as well as medical and health services and commercial businesses such as medical diagnosis, gene preservation, and pregnancy environment testing
.
The company’s third quarterly report showed that in the first three quarters, it achieved main operating income of 717 million yuan, a year-on-year increase of 19.
65%; net profit attributable to the parent was -5,387,500 yuan, a year-on-year increase of 95.
65%; deduction of non-net profit -30,534,100 yuan, a year-on-year increase of 78.
15%; In the third quarter of 2021, the company's single-quarter main operating income was 260 million yuan, a year-on-year increase of 26.
65%; the net profit attributable to the parent in a single quarter was -1.
2689 million yuan, a year-on-year increase of 97.
38%
.
In addition to the above-mentioned pharmaceutical companies, in November, Fuxiang shares and Tonghe Pharmaceutical received an increase of more than 5 million yuan.
In addition, Jiuqiang Biotech, Changchun High-tech, Lepu Medical, Kangenbei, Zhijiang Biotech, Sanxin Medical, Xianju Pharmaceutical and other pharmaceutical and biological companies have increased their holdings by more than 1 million yuan
.